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ABSTRACT 1 
 2 
Background and aims: since accelerated atherosclerosis has been reported in systemic lupus 3 
erythematosus (SLE), predictive biomarkers of cardiovascular disease (CVD) are needed. Among 4 
non-traditional risk factors, bone mineral density (BMD) has been related to CVD. However, its 5 
role in SLE remains controversial. This study aims to analyze the associations of subclinical 6 
atherosclerosis with traditional and non-traditional CV risk factors.  7 
Methods and results: in a cross-sectional study, atherosclerosis burden was compared between 112 8 
female SLE patients and 31 controls. Plaque number and carotid intima-media wall thickness 9 
(cIMT) were assessed by ultrasonography. In a retrospective study, BMD determinations obtained 10 
5-years before the ultrasonography assessment were analyzed in a subgroup of 62 patients. Plaque 11 
frequency was increased in SLE, even in patients without CV events or carotid wall thickening. 12 
cIMT was increased in patients with CVD, positively correlated with body mass index (BMI). 13 
Interestingly, a paradoxical effect of BMI on carotid parameters was observed. Whereas 14 
underweight patients (BMI<20) showed increased prevalence of carotid plaques with low cIMT, 15 
those with BMI>30 showed higher cIMT and plaque burden. Overweight patients (25<BMI<30) 16 
exhibited both elevated cIMT and plaque number. B I was an independent predictor of BMD. In 17 
our retrospective study, patients with either clinical or subclinical CVD exhibited lower BMD levels 18 
than their CV-free counterparts. A low lumbar spine BMD independently predicted CVD 19 
development after adjusting for confounders. 20 
Conclusion: SLE was associated with a higher subclinical atherosclerosis burden, a bimodal effect 21 
being observed for BMI. Decreased BMD can be a CV risk biomarker in SLE. 22 
 23 
 24 
Keywords: systemic lupus erythematosus, atherosclerosis, bone mineral disease, body mass index, 25 
subclinical cardiovascular disease  26 
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INTRODUCTION 1 
Cardiovascular disease (CVD) has a major impact on morbidity and mortality in systemic lupus 2 
erythematosus (SLE) (1), the prototypical systemic autoimmune disease. Recent evidence suggests 3 
an increased CV risk in patients at early disease stages or even at diagnosis. An increased 4 
prevalence of subclinical atherosclerosis, assessed by presence of carotid plaque and/or arterial wall 5 
thickening, has been observed in SLE patients (2–4). Moreover, subclinical atherosclerosis has been 6 
reported in young SLE patients without traditional risk factors (5). Actually, traditional CV risk 7 
cannot fully account for the increased CVD occurrence in SLE (6–8), hence supporting a role for 8 
chronic inflammation, autoimmunity and other SLE-related features. Therefore, the identification of 9 
novel biomarkers to be used in the clinical setting to identify patients at risk represents a major 10 
unmet need in this scenario. 11 
In recent years, a possible relationship between reduced bone mineral density (BMD) and CVD has 12 
emerged. BMD is also affected by inflammation and immune over-activation, and altered BMD is a 13 
frequent hallmark of SLE patients. The relationship between BMD and vascular calcifications was 14 
firstly described some time ago (9), but this association was probably under-estimated, since 15 
osteoporosis and vascular calcifications were originally considered as non-modifiable disorders of 16 
ageing. Currently, although the role of ageing cannot be completely dismissed, age-independent, 17 
direct biological links between bone metabolism and CVD have been described(10,11). However, 18 
the associations between bone metabolism and surrogate markers of CVD other than vascular 19 
calcification are under debate. In fact, contradictory results about the association between BMD and 20 
carotid atherosclerosis have been reported in SLE (12,13). Interestingly, reduced BMD has been 21 
associated with endothelial dysfunction in SLE (14), pointing to a very early crosstalk between 22 
BMD and CVD.  23 
Taking all these ideas into account, we aimed to evaluate (i) the prevalence of subclinical CVD 24 
(measured as atherosclerotic plaques and carotid arterial wall thickening) in SLE patients and the 25 
potential associations with traditional and non-traditional CV risk factors and (ii) the predictive 26 
value of 5-years retrospective BMD determination for the development of CVD in SLE. 27 
 28 
  29 
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MATERIAL AND METHODS 1 
Patients and controls 2 
This study encompasses both a cross-sectional and a retrospective sub-analyses. Our cross-sectional 3 
study involved 112 female SLE outpatient patients and 31 matched healthy volunteers from the 4 
same population as controls (see Online Supplementary Material). All patients fulfilled the 5 
American College of Rheumatology (ACR) revised criteria for the SLE classification (15). 6 
Traditional CV risk factors, parameters of disease activity (anti-dsDNA titer and SLE disease 7 
activity index, SLEDAI) and treatments received was obtained from clinical records (See Online 8 
Supplementary Material). A CV event was defined as previously described (16). For the 9 
retrospective sub-analysis, a subgroup of 62 female SLE patients who underwent a bone mass 10 
densitometry determination 5-years before the recruitment for the study was selected. Clinical 11 
features and demographic parameters at the time of BMD assessment were included in the analyses.  12 
Ethics approval was obtained from the Institutional Review Board (Regional Ethics Committee for 13 
Clinical Research, Servicio de Salud del Principado de Asturias, reference PI-16/00113), according 14 
to the Declaration of Helsinki. Written informed consent was signed from all individuals prior to 15 
enrollment. 16 
Carotid ultrasound assessments 17 
Doppler ultrasound assessment was performed using a Toshiba Aplio XG machine. The carotid 18 
intima-media wall thickness (cIMT) was bilaterally measured according to the “Mannheim Carotid 19 
Intima-Media Thickness Consensus (2004-2006)” (17) (see Online Supplementary Material). 20 
Plaque prevalence was considered as the frequency of patients exhibiting at least one plaque 21 
according to the previous consensus definition.   22 
Bone mineral density measurements 23 
Bone mineral density (BMD) was measured using a Hologic® QDR-4500 DXA densitometer. Both 24 
the postero-anterior lumbar spine (L2-L4) and the right proximal femur were analysed. 25 
Osteoporosis was defined according to World Health Organisation (WHO) criteria (18,19) (see 26 
Online Supplementary Material). Z- and T-scores were also calculated with the reference lumbar 27 
spine and proximal femur bone values of the Spanish population (19).  28 
Vascular calcifications were evaluated by X-rays (see Online Supplementary Material) (9,20,21), 29 
and the presence of osteoarthritis lesions was determined according to the Kellgren-Lawrence scale. 30 
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Statistical analyses 1 
Variables were summarized as mean ± standard deviation, median (interquartile range) or n(%), as 2 
appropriate. Differences between continuous variables were analysed by T, Mann-Withney U or 3 
Kruskal Wallis tests. For categorical variables, χ2 tests were performed. Multivariate analyses were 4 
carried out by multiple linear regression models or binary logistic regression. Demographic 5 
parameters, clinical features and traditional CV risk factors were entered in the models as 6 
covariates, as indicated. Odds Ratios (OR) and Relative Risk (RR), for binary logistic regression 7 
and B for linear regression, together with their respective 95% confidence intervals (CI) were 8 
computed (see Online Supplementary Material). A p-value<0.050 was considered the limit of 9 
statistical significance.  10 
  11 
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RESULTS 1 
Increased prevalence of subclinical atherosclerosis in SLE 2 
The presence of carotid atherosclerotic plaques and wall thickness (cIMT) in both left and right 3 
arteries were evaluated as surrogate markers of subclinical atherosclerosis in 112 female SLE 4 
patients and 31 matched healthy controls (HC). Demographic parameters, traditional CV risk 5 
factors and clinical features of the subjects involved in the study are summarized in the 6 
Supplementary Table 1. SLE patients showed increased prevalence of hypertension and obesity 7 
(BMI>30) and 16 of them have a previous history of CV events. Vascular ultrasonography revealed 8 
higher frequency of carotid plaques in SLE patients compared to HC (30.3% vs 9.6%, p=0.020), 9 
mainly in the left branch (Table 1). These findings were more evident in those who had suffered a 10 
CV event (Table 1). The mean number of plaques was also higher in patients, even in those without 11 
CVD (p=0.045). Conversely, the cIMT was only significantly increased in patients with previous 12 
CVD, thus supporting that SLE patients may present atherosclerotic plaques even in the absence of 13 
increased cIMT.  14 
Multivariate regression analysis including sex, age and traditional CV risk factors (dyslipidemia, 15 
hypertension, obesity and smoking habit) revealed that SLE patients presented more than 2-fold risk 16 
than HC for the development of atherosclerotic plaques (Table 2). A similar result was obtained 17 
when patients with previous CVD were excluded from the analysis (RR[95% CI]: 2.63[1.03, 8.50], 18 
p=0.038). Additionally, controlling for glucocorticoid usage at recruitment and ever use of high 19 
doses since diagnosis did not modify the association between SLE and plaque burden (RR[95% CI]: 20 
2.50[1.06, 7.89], p=0.039). Interestingly, a multivariate analysis in SLE patients including 21 
traditional CV risk factors, disease activity and duration, previous CVD and treatments (including 22 
current and ever use high doses of glucocorticoids) in the model (Supplementary Table 2) showed 23 
an unexpected protective role for BMI in the development of carotid plaques (RR[95% CI]: 24 
0.92[0.87, 0.98], p=0.015). Conversely, BMI was positively correlated with cIMT in patients 25 
(r=0.335, p<0.001), even after adjusting for sex, age and disease activity, duration and therapy 26 
usage (including current use of glucocorticoids and ever use of high doses of glucocorticoids, 27 
antimalarials and immunosuppresants) (β=0.253, p<0.001). Interestingly, patients with BMI>25 28 
(n=55) exhibited an increased cIMT compared with the under- and normal weight patients 29 
(p<0.001) and the HC group (p=0.022). Concurrent analysis of carotid plaques and cIMT in SLE 30 
patients categorized according to BMI showed that both under- and overweight patients exhibited 31 
higher prevalence of carotid plaques, hence suggesting a bimodal pattern, whereas cIMT was 32 
exhibited an increase in the overweight group and plateauing beyond BMI>30 (Figure 1). 33 
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Interestingly, quadratic curve fitting showed no increase in cIMT above BMI>30 (Figure 1). 1 
Exclusion of SLE patients with CVD from the analysis retrieved similar findings. Glucocorticoid 2 
usage was similar among BMI groups (p=0.432).  3 
Finally, we evaluated whether any SLE-related factors could be associated with the presence of 4 
carotid plaques using a multivariate logistic regression model. In a backward multistep analysis 5 
entering demographic variables, clinical features, treatments (including current use of 6 
glucocorticoids and ever use of high doses of glucocorticoids) and traditional CV risk factors in the 7 
initial model, only age (RR[95% CI]: 1.13[1.06, 1.20], p<0.001) and (RR[95% CI]: 2.51[1.02, 8 
7.42], p=0.043) showed a significant association. 9 
These results confirm an increased prevalence of subclinical atherosclerosis in female SLE patients 10 
and a paradoxical bimodal effect of BMI. Important differences between cIMT and plaque 11 
occurrence were disclosed.  12 
Low lumbar spine mineral density as a prognostic factor for CVD 13 
The possible predictive value of low bone mineral density (BMD) for the development of CVD was 14 
analyzed in a subgroup of 62 female SLE patients in whom the BMD at lumbar spine, femoral neck, 15 
total hip and Ward triangle had been determined 5 years before the vascular ultrasound 16 
examination. This subgroup was representative of the whole cohort of SLE patients regarding 17 
demographic, clinical and traditional CV risk factors. Data of BMD (g/cm2), T-score and Z-score at 18 
all bone sites, and concurrent clinical data (Supplementary Table 3), were analyzed in relation to the 19 
current CVD status, either clinical CVD or subclinical CVD (considered as presence of carotid 20 
plaques) (Figure 2).  21 
Interestingly, patients with either clinical or subclinical CVD exhibited a lower value of BMD 5 22 
years before, especially at lumbar spine. Therefore, both CVD groups were grouped and analyzed 23 
together thereafter. A logistic regression model including all bone mineral measurements, age, BMI, 24 
usage of high doses of glucocorticoids (>7.5 mg/day ever since diagnosis), immunosuppressants 25 
(since diagnosis), history of previous fractures, menopause status, and the presence of osteoarthritis 26 
lesions and vascular calcifications at the time of densitometry, revealed that low lumbar spine 27 
mineral density was an independent predictive factor for CVD development (Table 3). Actually, 28 
low lumbar BMD (defined either as osteopenia [n=18] or osteoporosis [n=12] according to the 29 
reference values) was associated with an increased risk of CVD development (OR[95% CI], p: 30 
6.411[1.134, 36.239], p=0.036) after adjusting for potential confounders. Importantly, this 31 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
association was already observed in patients with osteopenia (5.161[1.126, 52.181], p=0.040), 1 
whereas a separate analysis on their osteoporosis counterparts alone did not exhibit such association 2 
(1.276[0.090, 18.080], p=0.857). Interestingly, BMD determinations at any bone site were not 3 
predictive of cIMT values (Supplementary Table 4).  4 
It is noteworthy that BMI (at the time of densitometry) was an independent predictor of BMD at all 5 
bone sites in linear regression analyses adjusted for age (lumbar spine: β=0.317, p=0.028; femoral 6 
neck: β=0.516, p<0.001; total hip: β=0.473, p=0.001, and Ward triangle: β=0.289, p=0.072). Use of 7 
high dosages of glucocorticoids (either at the time of BMD measurement and ever use since 8 
diagnosis) was not found to have an effect on these associations. Similarly, these associations 9 
remained after controlling for menopause and history of previous fractures. Moreover, no 10 
association was found between BMD and presence of vascular calcifications or osteoarthritis 11 
lesions.   12 
Overall, our findings confirm that a low BMD can be an independent predictor of CVD occurrence 13 
in SLE patients. Additionally, a positive association between BMI and BMD is disclosed.  14 
  15 
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DISCUSSION 1 
Although a compelling body of evidence supports an increased prevalence of CVD in SLE, the 2 
origin of this increased risk remains elusive and new biomarkers allowing early identification of 3 
patients at risk are needed. Apart from vascular homeostasis, bone metabolism has been largely 4 
reported to be altered in SLE. In the present work we have explored the potential links between 5 
these two conditions and we have reported, for the first time, that a low BMD at lumbar spine 6 
predict clinical and subclinical CV events occurrence in female SLE patients. Additionally, a 7 
paradoxical bimodal effect of BMI on atherosclerosis burden was observed.  8 
In line with the prevalence reported by other authors (2–4), about one third of our SLE patients 9 
presented carotid plaques, suggestive of subclinical atherosclerosis, even in the absence of a 10 
substantial cIMT increase. In fact, a significant arterial wall thickening was only detected in patients 11 
with CVD, whereas SLE patients without previous history of CV events have near 3-fold higher 12 
frequency of carotid plaques than controls after adjusting for traditional CV risk factors. These 13 
results highlight important differences between both ultrasound findings. Although frequently 14 
considered as synonymous assessments, our results underline important differences between them, 15 
in line with other studies in immune-mediated conditions (22,23). Of note, cIMT not only 16 
represents subclinical atherosclerosis but it is also influenced by non-atherosclerotic wall 17 
remodeling (17). However, the presence of plaque is of overriding importance in reflecting 18 
cardiovascular risk (24). Therefore, all these lines of evidence point to a complementary, different 19 
interpretation of cIMT and plaque number, especially in immune-mediated diseases. Whether these 20 
discrepancies are also the consequence of different underlying mechanisms warrants further studies.  21 
An interesting result from our study was the apparently paradoxical effect of the BMI on the 22 
development of subclinical atherosclerosis in SLE. The worst carotid parameters, high both cIMT 23 
and plaque number, were observed in overweight patients. However, underweight (BMI<20) was 24 
found to be detrimental for plaque development with no effect on cIMT, whereas obese patients 25 
(BMI>30) were less likely to exhibit carotid plaques in spite of the increased cIMT. All these 26 
findings reflect the complex relationship between BMI and CVD and are in agreement with the so-27 
called “obesity paradox”, a term coined to explain the epidemiologic observation of a protective 28 
effect of obesity on CVD outcomes in several studies (25–27). A number of quantitative and 29 
qualitative concepts emerge from these findings. First, from a quantitative point of view, although 30 
high BMI has been largely recognized as an independent CV risk factor in the general population, 31 
recent epidemiological studies have challenged this notion by reporting better survival outcomes in 32 
obese patients than in their non-obese counterparts in a wide range of chronic diseases, from heart 33 
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failure and other CVD to chronic kidney disease (28), chronic obstructive lung disease (29), 1 
hypertension, type 2 diabetes (30), rheumatoid arthritis (31) or osteoporosis (32). Interestingly, 2 
Sacre and colleagues have found that overweight is the main contribution to atherosclerosis in SLE 3 
patients (33). However, no separate analysis of underweight and obese patients has been performed, 4 
which makes difficult the comparison between studies. On the other hand, a non-linear effect of 5 
BMI has been reported elsewhere (34,35), which is in accordance with our results. These findings 6 
may suggest that the effect of obesity cannot be solely explained by the quantity of adipose tissue, 7 
hence pointing to qualitative aspects such us its composition, metabolic status or location in the 8 
body. As a consequence, a multifactorial origin emerges from the obesity paradox, thus explaining, 9 
at least partially, the heterogeneous results obtained elsewhere.  10 
In fact, there are some pieces of evidence underlining the limitations of the use of BMI as a measure 11 
of obesity (36). This is especially evident in immune-driven conditions, where an altered body 12 
composition is widely recognized (37,38) and anthropometrical measures have yielded 13 
contradictory results (39). It is important to note that body composition, and thus the qualitative 14 
effects of obesity, may also differ by gender. However, our study was focused on female SLE 15 
patients, hence allowing us to avoid a potential confounding effect of gender. Additionally, other 16 
mechanisms associated to adipose tissue are probably involved, such as the secretion of a variety of 17 
adipokines or soluble receptors, with different, and frequently controversial, effects on CVD (40–18 
44). Finally, several studies have revealed some controversy with regards to the association between 19 
BMI and cIMT or plaque numbers (12,13), different associations being observed for each surrogate 20 
marker. On the one hand, these findings add to the current complexity of the “obesity paradox”. On 21 
the other hand, these divergent associations may point to different mechanisms underlying cIMT 22 
and plaque development in SLE, thereby supporting our previous results. Interestingly, Ajeganova 23 
and colleagues found a considerable number of clinical parameters independently associated with 24 
plaque formation in SLE patients, including low C4, disease duration and activity score, but not for 25 
cIMT, which was strongly associated with BMI (13). Our analyses revealed an association of 26 
plaque burden with the presence of serositis, a complication of SLE. Taken together, these data lead 27 
us to consider that plaque development may be more actively influenced by chronic inflammation 28 
and impaired immune response, whereas the cIMT may be more dependent of the BMI, probably 29 
because of hemodynamic factors (36).  30 
Overall, the results herein reported allow us to propose a new CV-protective mechanism of adipose 31 
tissue, at least in female SLE patients, since a decreased BMD, associated to a low BMI, was a clear 32 
predictive factor of CVD in these patients. The predictive value of a low BMD for the development 33 
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of CVD in SLE patients detected in this study is in line with the relationship between osteoporosis 1 
and atherosclerosis reported in several large observational studies (45–47). However, contradictory 2 
results have been found in SLE patients, since both an association between BMD and carotid 3 
plaques (13) and a lack of it (12) have been recently reported. Nevertheless, methodological 4 
differences between studies must be acknowledged. Since both atherosclerosis development and 5 
bone turnover are progressive, long-lasting processes, we evaluated the predictive potential of BMD 6 
assessment for the development of clinical or subclinical CVD along the disease course. We found 7 
that low BMD at lumbar spine can be proposed as a novel CV risk factor in female SLE patients. 8 
Importantly, although previously linked to endothelial dysfunction (14), our findings were further 9 
by demonstrating an association with both clinical and subclinical CVD occurrence in SLE. 10 
Interestingly, glucocorticoids usage was not associated with CV endpoints in our study, hence 11 
ruling out the possibility of a potential confounding effect (either by indication bias or a potential 12 
glucocorticoid-dependent bone loss). Moreover, our results showed a predictive value of low BMD 13 
even at subclinical osteopenia levels, hence expanding the established idea about the association 14 
between clinical osteoporosis and CVD and adding to the clinical value to the subclinical bone loss 15 
in this setting.     16 
It could be hypothesized a protective effect of adipose tissue in SLE patients that could be partly 17 
attributed to the preservation of an adequate mineral density over time, whereas at low BMI the 18 
bone loss is enhanced. Actually, our results confirm a positive association between BMI and BMD. 19 
Low BMI is a well-known risk factor for decreased BMD and fragility fracture (32,48). 20 
Nevertheless, a larger BMI confers greater mechanical loading on bone, enhancing its capacity to 21 
accommodate the heavier load. Hence, it is feasible that a low BMI may be related to an altered 22 
bone storage capacity, which may ultimately affect the promotion of atherosclerosis, hence 23 
suggesting a link among BMI, bone metabolism and (cardio)vascular homeostasis along disease 24 
course.  25 
Finally, although different bone locations were analyzed in the present study, only lumbar spine 26 
remained as an independent predictor of CVD development in multivariate analyses. Similar results 27 
were published by our group (20) when looking at vascular calcifications. These results reinforce 28 
the idea that bone loss might occur first in trabecular bone (lumbar spine) instead in cortical bone 29 
(proximal femur), as previously suggested (49). This is also in line with previous studies by other 30 
groups in SLE (50). Consequently, this will facilitate the implementation of BMD as a novel risk 31 
biomarker in the clinical setting. The strong association between low BMD and CVD occurrence 32 
proved these findings worthy of further research to improve clinical management in this condition. 33 
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Similarly, although our results confirm its predictive value over a 5-years period, whether other 1 
time-points may be useful requires further elucidation. 2 
In summary, our findings confirm an increased prevalence of subclinical atherosclerosis in female 3 
SLE patients compared to healthy controls. Whereas plaque development was observed in patients 4 
free of CV events, cIMT was only increased in those with a history of previous CVD and in patients 5 
with high BMI. Furthermore, although age and serositis were independently associated with 6 
atherosclerotic plaques, a paradoxical association was observed for BMI. Additionally, the most 7 
striking finding, not previously reported, was that sub-clinically low BMD, beyond the osteoporosis 8 
threshold, at lumbar spine emerged as an independent CVD predictor in a retrospective analysis. 9 
Importantly, low BMD was associated with a low BMI, thus suggesting a crosstalk between bone 10 
metabolism and cardiovascular traits in SLE. It is important to consider that our study was 11 
developed under a retrospective design and, as such, intrinsic bias may represent a potential 12 
limitation. However, an appropriate management and analysis of clinical datasets to minimize its 13 
possible effect was performed.   14 
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HIGHLIGHTS 1 
 2 
• Atherosclerosis is found in female SLE patients without CV disease (CVD) or increased 3 
cIMT 4 
• A paradoxical, negative association between obesity and plaque burden is found 5 
• BMI is an independent predictor of bone mineral density (BMD) in female SLE patients 6 
• Low BMD predicts clinical or subclinical CVD development in SLE  7 
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FIGURE LEGENDS 1 
 2 
Figure 1: Association between BMI and cIMT in SLE female patients. Our data showed fitted 3 
best to a quadratic curve fitting. No effect of BMI beyond 30 kg/m2 was observed on cIMT values. 4 
However, a bimodal distribution was observed for plaque development. Patients with obesity 5 
exhibited the lowest plaque number among BMI groups (table below graph). Presence of carotid 6 
plaques was calculated as the frequency of patients with at least one plaque within the group sample 7 
population (indicated in each column. Differences were assessed by Kruskal-Wallis or χ2test.  8 
 9 
Figure 2: Analysis of retrospective BMD determinations and CV status in female SLE 10 
patients. BMD determinations (BMD, T-score and Z-score) at different bone sites (lumbar spine, 11 
femoral neck, total hip and Ward triangle) obtained 5 years before ultrasonography determination 12 
were compared in SLE patients among groups: no CVD (free of CV events, n= 33), subclinical 13 
CVD (defined as the presence of carotid plaques, n=16) and CVD (occurrence of a past CV event, 14 
n=13). BMD values are represented according to left Y-axis (g/cm2), whereas those of Z- and T-15 
scores are to the left Y-axis (score). Boxes represent median as well as first and third quartiles, and 16 
the lines outside the boxes represent the minimum and maximum values. Differences were 17 
evaluated by Kruskal-Wallis test and Dunn-Bonferroni correction for multiple comparisons tests. 18 
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Table 1. Prevalence of atherosclerotic plaques in controls and SLE patients. 
 
 
 
 
 
 
 
 
Variables were summarized as mean±SD, median (IQR) or n(%). a Presence of carotid plaques was calculated as the 
frequency of patients with at least one plaque within the whole population. Statistical differences were assessed by 
Kruskal-Wallis or χ2 tests, as appropriate. cIMT: coronary intima-media thickness.   
 
 
HC 
(n=31) 
SLE without 
CVD (n=96) 
SLE with 
CVD (n=16) p-value 
Presence of carotid plaquesa, n (%)     
        Left  2 (6.5) 21 (21.9) 6 (37.5) 0.034 
        Right 3 (9.7) 21 (21.9) 5 (31.3) 0.174 
        Left + Right 3 (9.7) 26 (27.1) 8 (50.0) 0.009 
Plaque number, mean ± SD 0.13 ± 0.42 0.49 ± 0.87 0.81 ± 0.50 0.014 
cIMT (mm), median (IQR)     
       Left 0.56 (0.07) 0.56 (0.10) 0.70 (0.24) 0.022 
       Right 0.56 (0.16) 0.56 (0.19) 0.58 (0.19) 0.240 
       Mean 0.56 (0.12) 0.57 (0.10) 0.67 (0.21) 0.044 
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Table 2. Relative risk for change in the number of atherosclerotic plaques in SLE 
compared with controls. 
 Relative risk 95% CI p-value 
SLE 2.884 1.027, 8.098 0.039 
Age 1.074 1.038, 1.111 <0.001 
BMI  0.710 0.563, 0.980 0.040 
Smoking 1.446 0.636, 3.289 0.378 
Dyslipidemia 1.167 0.482, 2.823 0.732 
Hypertension 1.853 0.784, 4.380 0.160 
 
Relative risks (RR) and 95% CI were computed from multivariate negative binomial regression models.  
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